Switch to:
Also traded in: Germany, Mexico

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.31
MCK's Cash-to-Debt is ranked lower than
72% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.66 vs. MCK: 0.31 )
Ranked among companies with meaningful Cash-to-Debt only.
MCK' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.49 Max: 3.01
Current: 0.31
0.05
3.01
Equity-to-Asset 0.18
MCK's Equity-to-Asset is ranked lower than
88% of the 58 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.41 vs. MCK: 0.18 )
Ranked among companies with meaningful Equity-to-Asset only.
MCK' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.13  Med: 0.26 Max: 0.35
Current: 0.18
0.13
0.35
Debt-to-Equity 0.75
MCK's Debt-to-Equity is ranked lower than
60% of the 53 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.48 vs. MCK: 0.75 )
Ranked among companies with meaningful Debt-to-Equity only.
MCK' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.16  Med: 0.48 Max: 1.51
Current: 0.75
0.16
1.51
Debt-to-EBITDA 1.14
MCK's Debt-to-EBITDA is ranked higher than
71% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.03 vs. MCK: 1.14 )
Ranked among companies with meaningful Debt-to-EBITDA only.
MCK' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.91  Med: 1.61 Max: 3.3
Current: 1.14
0.91
3.3
Interest Coverage 22.32
MCK's Interest Coverage is ranked higher than
62% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.55 vs. MCK: 22.32 )
Ranked among companies with meaningful Interest Coverage only.
MCK' s Interest Coverage Range Over the Past 10 Years
Min: 7.94  Med: 9.12 Max: 23.08
Current: 22.32
7.94
23.08
Piotroski F-Score: 4
Altman Z-Score: 4.16
Beneish M-Score: -2.12
WACC vs ROIC
8.31%
31.62%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 3.18
MCK's Operating Margin % is ranked lower than
57% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.74 vs. MCK: 3.18 )
Ranked among companies with meaningful Operating Margin % only.
MCK' s Operating Margin % Range Over the Past 10 Years
Min: 1.12  Med: 1.76 Max: 3.58
Current: 3.18
1.12
3.58
Net Margin % 2.24
MCK's Net Margin % is ranked higher than
52% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.81 vs. MCK: 2.24 )
Ranked among companies with meaningful Net Margin % only.
MCK' s Net Margin % Range Over the Past 10 Years
Min: 0.77  Med: 1.08 Max: 2.55
Current: 2.24
0.77
2.55
ROE % 44.70
MCK's ROE % is ranked higher than
98% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.64 vs. MCK: 44.70 )
Ranked among companies with meaningful ROE % only.
MCK' s ROE % Range Over the Past 10 Years
Min: 13.37  Med: 18.14 Max: 50.65
Current: 44.7
13.37
50.65
ROA % 7.48
MCK's ROA % is ranked higher than
90% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.48 vs. MCK: 7.48 )
Ranked among companies with meaningful ROA % only.
MCK' s ROA % Range Over the Past 10 Years
Min: 2.79  Med: 4.08 Max: 8.63
Current: 7.48
2.79
8.63
ROC (Joel Greenblatt) % 214.21
MCK's ROC (Joel Greenblatt) % is ranked higher than
97% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 22.84 vs. MCK: 214.21 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MCK' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 63.18  Med: 122.48 Max: 261.54
Current: 214.21
63.18
261.54
3-Year Revenue Growth Rate 14.70
MCK's 3-Year Revenue Growth Rate is ranked higher than
67% of the 49 Companies
in the Global Medical Distribution industry.

( Industry Median: 8.60 vs. MCK: 14.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MCK' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -13.6  Med: 11.5 Max: 23.7
Current: 14.7
-13.6
23.7
3-Year EBITDA Growth Rate 38.30
MCK's 3-Year EBITDA Growth Rate is ranked higher than
91% of the 43 Companies
in the Global Medical Distribution industry.

( Industry Median: 7.90 vs. MCK: 38.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MCK' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -52.7  Med: 11.75 Max: 171.6
Current: 38.3
-52.7
171.6
3-Year EPS without NRI Growth Rate 56.40
MCK's 3-Year EPS without NRI Growth Rate is ranked higher than
95% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.10 vs. MCK: 56.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MCK' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44.5  Med: 13.3 Max: 87.1
Current: 56.4
-44.5
87.1
GuruFocus has detected 1 Warning Sign with McKesson Corp MCK.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MCK's 30-Y Financials

Financials (Next Earnings Date: 2018-01-25)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q4 2016

MCK Guru Trades in Q4 2016

Seth Klarman 1,000,000 sh (New)
Richard Pzena 186,289 sh (New)
David Tepper 275,000 sh (New)
Larry Robbins 683,516 sh (New)
Steven Cohen 43,100 sh (New)
Jana Partners 386,868 sh (New)
Charles Brandes 1,045,486 sh (+1796.26%)
Diamond Hill Capital 21,280 sh (+1464.71%)
Jerome Dodson 119,000 sh (+197.50%)
Paul Tudor Jones 26,546 sh (+184.74%)
Ray Dalio 67,759 sh (+63.83%)
Ronald Muhlenkamp 71,767 sh (+56.86%)
Joel Greenblatt 277,057 sh (+17.78%)
Vanguard Health Care Fund 8,218,500 sh (+14.70%)
Mario Gabelli 5,000 sh (unchged)
Tom Gayner 9,100 sh (unchged)
Wallace Weitz Sold Out
John Paulson Sold Out
Jim Simons Sold Out
Eaton Vance Worldwide Health Sciences Fund Sold Out
Scott Black 8,813 sh (-2.46%)
Arnold Van Den Berg 66,107 sh (-2.70%)
John Buckingham 21,226 sh (-4.13%)
Manning & Napier Advisors, Inc 38,800 sh (-14.25%)
David Dreman 3,925 sh (-21.56%)
First Pacific Advisors 57,200 sh (-31.15%)
» More
Q1 2017

MCK Guru Trades in Q1 2017

George Soros 1,400 sh (New)
Richard Pzena 2,077,104 sh (+1014.99%)
Steven Cohen 358,500 sh (+731.79%)
Scott Black 15,006 sh (+70.27%)
Jerome Dodson 168,000 sh (+41.18%)
Larry Robbins 917,776 sh (+34.27%)
Arnold Van Den Berg 80,140 sh (+21.23%)
Charles Brandes 1,121,845 sh (+7.30%)
John Buckingham 21,254 sh (+0.13%)
Mario Gabelli 5,000 sh (unchged)
David Dreman 3,925 sh (unchged)
Seth Klarman 1,000,000 sh (unchged)
Tom Gayner 9,100 sh (unchged)
Jana Partners Sold Out
Diamond Hill Capital 21,251 sh (-0.14%)
Ronald Muhlenkamp 71,430 sh (-0.47%)
Vanguard Health Care Fund 8,002,819 sh (-2.62%)
First Pacific Advisors 48,300 sh (-15.56%)
Ray Dalio 57,101 sh (-15.73%)
Manning & Napier Advisors, Inc 26,355 sh (-32.07%)
Paul Tudor Jones 15,721 sh (-40.78%)
Joel Greenblatt 129,666 sh (-53.20%)
David Tepper 100,000 sh (-63.64%)
» More
Q2 2017

MCK Guru Trades in Q2 2017

Jim Simons 1,000,900 sh (New)
Joel Greenblatt 263,216 sh (+103.00%)
David Dreman 6,834 sh (+74.11%)
Tom Gayner 15,100 sh (+65.93%)
Steven Cohen 571,716 sh (+59.47%)
Larry Robbins 1,187,828 sh (+29.42%)
Diamond Hill Capital 23,983 sh (+12.86%)
Arnold Van Den Berg 87,950 sh (+9.75%)
Richard Pzena 2,097,855 sh (+1.00%)
Jerome Dodson 168,000 sh (unchged)
Vanguard Health Care Fund 8,002,819 sh (unchged)
Mario Gabelli 5,000 sh (unchged)
Louis Moore Bacon 80,000 sh (unchged)
Seth Klarman Sold Out
David Tepper Sold Out
George Soros Sold Out
Scott Black Sold Out
Ronald Muhlenkamp 71,365 sh (-0.09%)
John Buckingham 21,044 sh (-0.99%)
Charles Brandes 979,257 sh (-12.71%)
Ray Dalio 48,708 sh (-14.70%)
Manning & Napier Advisors, Inc 21,370 sh (-18.91%)
Paul Tudor Jones 12,476 sh (-20.64%)
First Pacific Advisors 26,550 sh (-45.03%)
» More
Q3 2017

MCK Guru Trades in Q3 2017

Seth Klarman 500,000 sh (New)
George Soros 69,000 sh (New)
Larry Robbins 2,720,878 sh (+129.06%)
Tom Gayner 26,100 sh (+72.85%)
Richard Pzena 2,458,531 sh (+17.19%)
John Buckingham 22,495 sh (+6.90%)
Jerome Dodson 168,000 sh (unchged)
Vanguard Health Care Fund 8,002,819 sh (unchged)
Mario Gabelli 5,000 sh (unchged)
David Dreman 6,834 sh (unchged)
First Pacific Advisors 26,550 sh (unchged)
Paul Tudor Jones Sold Out
Ronald Muhlenkamp 70,956 sh (-0.57%)
Manning & Napier Advisors, Inc 20,970 sh (-1.87%)
Arnold Van Den Berg 85,965 sh (-2.26%)
Joel Greenblatt 222,026 sh (-15.65%)
Charles Brandes 730,251 sh (-25.43%)
Ray Dalio 34,346 sh (-29.49%)
Jim Simons 565,200 sh (-43.53%)
Diamond Hill Capital 3,782 sh (-84.23%)
Steven Cohen 45,000 sh (-92.13%)
» More
» Details

Insider Trades

Latest Guru Trades with MCK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Pzena 2017-09-30 Add 17.19%0.29%$146 - $168.12 $ 142.13-9%2,458,531
Charles Brandes 2017-09-30 Reduce -25.43%0.65%$146 - $168.12 $ 142.13-9%730,251
Seth Klarman 2017-09-30 New Buy0.96%$146 - $168.12 $ 142.13-9%500,000
Joel Greenblatt 2017-09-30 Reduce -15.65%0.1%$146 - $168.12 $ 142.13-9%222,026
Arnold Van Den Berg 2017-09-30 Reduce -2.26%0.05%$146 - $168.12 $ 142.13-9%85,965
Ronald Muhlenkamp 2017-09-30 Reduce -0.57%0.02%$146 - $168.12 $ 142.13-9%70,956
George Soros 2017-09-30 New Buy0.32%$146 - $168.12 $ 142.13-9%69,000
Tom Gayner 2017-09-30 Add 72.85%0.03%$146 - $168.12 $ 142.13-9%26,100
Richard Pzena 2017-06-30 Add 1.00%0.02%$135 - $167.61 $ 142.13-6%2,097,855
Charles Brandes 2017-06-30 Reduce -12.71%0.31%$135 - $167.61 $ 142.13-6%979,257
Joel Greenblatt 2017-06-30 Add 103.00%0.31%$135 - $167.61 $ 142.13-6%263,216
Arnold Van Den Berg 2017-06-30 Add 9.75%0.2%$135 - $167.61 $ 142.13-6%87,950
Ronald Muhlenkamp 2017-06-30 Reduce -0.09%$135 - $167.61 $ 142.13-6%71,365
Tom Gayner 2017-06-30 Add 65.93%0.02%$135 - $167.61 $ 142.13-6%15,100
David Dreman 2017-06-30 Add 74.11%0.26%$135 - $167.61 $ 142.13-6%6,834
Seth Klarman 2017-06-30 Sold Out 1.76%$135 - $167.61 $ 142.13-6%0
David Tepper 2017-06-30 Sold Out 0.24%$135 - $167.61 $ 142.13-6%0
George Soros 2017-06-30 Sold Out 0.01%$135 - $167.61 $ 142.13-6%0
Vanguard Health Care Fund 2017-03-31 Reduce -2.62%0.07%$136.74 - $152.53 $ 142.13-3%8,002,819
Richard Pzena 2017-03-31 Add 1014.99%1.58%$136.74 - $152.53 $ 142.13-3%2,077,104
Charles Brandes 2017-03-31 Add 7.30%0.17%$136.74 - $152.53 $ 142.13-3%1,121,845
Joel Greenblatt 2017-03-31 Reduce -53.20%0.27%$136.74 - $152.53 $ 142.13-3%129,666
David Tepper 2017-03-31 Reduce -63.64%0.43%$136.74 - $152.53 $ 142.13-3%100,000
Arnold Van Den Berg 2017-03-31 Add 21.23%0.31%$136.74 - $152.53 $ 142.13-3%80,140
Ronald Muhlenkamp 2017-03-31 Reduce -0.47%0.01%$136.74 - $152.53 $ 142.13-3%71,430
George Soros 2017-03-31 New Buy0.01%$136.74 - $152.53 $ 142.13-3%1,400
Vanguard Health Care Fund 2016-12-31 Add 14.70%0.35%$124.11 - $165.82 $ 142.13-3%8,218,500
Charles Brandes 2016-12-31 Add 1796.26%2.08%$124.11 - $165.82 $ 142.13-3%1,045,486
Seth Klarman 2016-12-31 New Buy1.85%$124.11 - $165.82 $ 142.13-3%1,000,000
Joel Greenblatt 2016-12-31 Add 17.78%0.08%$124.11 - $165.82 $ 142.13-3%277,057
David Tepper 2016-12-31 New Buy0.68%$124.11 - $165.82 $ 142.13-3%275,000
Richard Pzena 2016-12-31 New Buy0.15%$124.11 - $165.82 $ 142.13-3%186,289
Ronald Muhlenkamp 2016-12-31 Add 56.86%1.15%$124.11 - $165.82 $ 142.13-3%71,767
Arnold Van Den Berg 2016-12-31 Reduce -2.70%0.05%$124.11 - $165.82 $ 142.13-3%66,107
David Dreman 2016-12-31 Reduce -21.56%0.11%$124.11 - $165.82 $ 142.13-3%3,925
Wallace Weitz 2016-12-31 Sold Out 0.37%$124.11 - $165.82 $ 142.13-3%0
John Paulson 2016-12-31 Sold Out 0.12%$124.11 - $165.82 $ 142.13-3%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Distribution » Medical Distribution    NAICS: 424210    SIC: 5122
Compare:NYSE:CAH, NYSE:ABC, HKSE:01099, NAS:HSIC, SHSE:601607, XKRX:091990, SHSE:600056, TSE:7459, SZSE:200028, SZSE:002589, NAS:PDCO, LSE:UDG, NYSE:PBH, SHSE:600090, NZSE:EBO, LSE:CLIN, NYSE:OMI, SHSE:603368, SHSE:600763, SZSE:002551 » details
Traded in other countries:MCK.Germany, MCK.Mexico,
Headquarter Location:USA
McKesson Corp provides medicines, pharmaceutical supplies, information and care management products and services across the healthcare industry. It operates with two segments namely McKesson Distribution Solutions and McKesson Technology Solutions.

McKesson is a major distributor of pharmaceuticals, specialty drugs, and medical products in North America. The firm plays a critical role along the pharmaceutical supply chain as it is able to procure and distribute drugs more efficiently than its pharmacy client and pharma manufacturing suppliers.

Guru Investment Theses on McKesson Corp

Weitz Funds Comments on McKesson - Jan 26, 2017

McKesson (NYSE:MCK) distributes drugs, equipment and health and beauty care products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Shares of McKesson declined in October as the company experienced unexpected competitive losses from its core independent pharmacy customer base. The source (price competition) and magnitude of these developments led to a downward revision in McKesson’s earnings power and undermined one of the pillars of our investment thesis – that drug wholesalers operate within a competitive, but otherwise rational, oligopoly. Our estimate of McKesson’s business value declined, and we elected to close our small position at a modest loss.



From Weitz Investment Management's Value Fund fourth quarter 2016 commentary.



Check out Wallace Weitz latest stock trades

Mario Gabelli Comments on McKesson Corp - Jul 26, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.

From Mario Gabelli (Trades, Portfolio)'s Gabelli Asset Fund second quarter 2016 commentary.

Check out Mario Gabelli latest stock trades

Mario Gabelli Comments on McKesson Corp - Jul 25, 2016

McKesson Corp. (NYSE:MCK) (0.1%) (MCK – $186.65 – NYSE) is one of the three largest drug wholesalers in the world and has been expanding aggressively outside the U.S. through the acquisition of Celesio and several other European companies. McKesson recently announced an innovative divestiture of its information technology businesses; it will merge it with privately owned Change Healthcare and the combined company will go public next year. In its core wholesaling business, the company has stabilized its performance after several contract losses, recently signing a large new contract with Walmart. McKesson retains a balanced capital return policy that invests first in its core business but then returns a significant amount of cash to shareholders via dividends and share repurchases, which has helped the company post superior long term growth and returns.



From the Gabelli ABC Merger Arbitrage Fund second quarter 2016 shareholder letter.



Check out Mario Gabelli latest stock trades

Parnassus Fund Comments on McKesson - May 09, 2016

McKesson (NYSE:MCK), the largest drug distributor in the nation, sliced 50 basis points from the Fund’s return, as the stock declined 20.3% from $197.23 to $157.25. The stock moved lower after management provided weaker-than-expected guidance due to weaker generic drug prices. McKesson also lost some drugstore customers, as several chains were acquired by firms using other distributors. Despite these headwinds, we expect revenue to recover through organic growth and attracting new customers. McKesson provides significant value to consumers by improving the efficiency of drug procurement and delivery, which we believe will generate shareholder value over the long term.



From the Parnassus Fund first quarter 2016 shareholder letter.



Check out Jerome Dodson latest stock trades

Wallace Weitz Comments on McKesson - Apr 22, 2016

McKesson (NYSE:MCK) distributes drugs, equipment, and health and beauty products throughout North America and portions of Europe. The company also delivers software solutions and outsourced services to hospitals, pharmacies and other healthcare organizations. Merger-related customer losses (McKesson accounts Omnicare, Target Pharmacy and Rite Aid are moving to competing wholesalers after being acquired), the return of generic drug deflation and concerns of lower future branded drug inflation combined to drive McKesson’s stock down nearly 40% from its high last summer. Having done detailed work on the company roughly nine years prior, we sharpened our pencils again late last year and initiated a position at $150 in January. The drug wholesaling business is an attractive oligopoly characterized by intense but rational competition, stable growth, healthy returns on capital and consistent excess cash generation. While McKesson’s business faces some near-term headwinds, we believe it is an attractive investment over the long term.

From Wallace Weitz (Trades, Portfolio)'s Weitz Value Fund 1st quarter 2016 commentary.

Check out Wallace Weitz latest stock trades

Top Ranked Articles about McKesson Corp

New Research Coverage Highlights Zions, McKesson, Sealed Air, CenterPoint Energy, Coca-Cola European Partners, and KKR & Co. — Consolidated Revenues, Company Growth, and Expectations for 2018
Klarman's Top Buys for the 3rd Quarter The guru added 4 stocks to his portfolio
Seth Klarman (Trades, Portfolio)’s Baupost Group did not make many portfolio changes during the third quarter, but the positions added were, as always, interesting. Read more...
Seth Klarman Is Betting on Energy and Health Care Investing giant picks four new stocks mostly from his favored sectors
A king of the value hedge fund scene, Seth Klarman (Trades, Portfolio) picked four stocks for his concentrated portfolio that bets on only 36 stocks as of the end of the third quarter, according to his portfolio update released Monday. Read more...
Tom Gayner Keeps Adding to Facebook, Apple, Starbucks The guru purchased these stocks in the last 2 quarters
Markel Corp. (NYSE:MKL) Executive Vice President and Chief Investment Officer and Markel Gayner Asset Management Inc. President Tom Gayner (Trades, Portfolio) manages a portfolio with a total value of $5.023 billion. In both the second and third quarters the guru bought shares in the following stocks: Read more...
Wall Street Opens Higher Thursday Twitter jumps on earnings beat
Wall Street is in the green on the news the European Central Bank will extend its bond buying program through September 2018. The new plan will start in January. Read more...
Insiders Roundup: Twitter, McKesson Make Biggest Trades Largest insider trades of the Week
The GuruFocus All-in-One Screener can be used to find insider trades from the past week. Under the Insiders tab, change the settings for All Insider Buying to “$200,000+,” the duration to “Sept. 2017” and All Insider Sales to “$5,000,000+." Read more...
Steven Cohen Plunges Into Opioid Replacement Maker Pacira Point72 bolsters position more than a thousand percent
Steven Cohen (Trades, Portfolio), founder of Point72 Asset Management, made a 1098% increase to his holding of Pacira Pharmaceuticals (NASDAQ:PCRX), he revealed this week. Read more...
Van Den Berg Buys Dollar Tree, Schlumberger, CVS Largest 2nd-quarter purchases by the guru
During the second quarter Arnold Van Den Berg (Trades, Portfolio) bought shares in the following stocks: Read more...
Allscripts to acquire McKesson’s Enterprise Information Solutions business
6 Stocks Arnold Van Den Berg Keeps Buying The guru bought these stocks in the last 2 quarters
Century Management founder Arnold Van Den Berg (Trades, Portfolio) bought shares of the following stocks in both the first and second quarters: Read more...

Ratios

vs
industry
vs
history
PE Ratio 6.94
MCK's PE Ratio is ranked higher than
94% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.42 vs. MCK: 6.94 )
Ranked among companies with meaningful PE Ratio only.
MCK' s PE Ratio Range Over the Past 10 Years
Min: 5.98  Med: 17.64 Max: 38.44
Current: 6.94
5.98
38.44
Forward PE Ratio 11.75
MCK's Forward PE Ratio is ranked higher than
80% of the 15 Companies
in the Global Medical Distribution industry.

( Industry Median: 13.55 vs. MCK: 11.75 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 6.93
MCK's PE Ratio without NRI is ranked higher than
96% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 21.66 vs. MCK: 6.93 )
Ranked among companies with meaningful PE Ratio without NRI only.
MCK' s PE Ratio without NRI Range Over the Past 10 Years
Min: 5.83  Med: 17.33 Max: 33.83
Current: 6.93
5.83
33.83
Price-to-Owner-Earnings 5.12
MCK's Price-to-Owner-Earnings is ranked higher than
91% of the 34 Companies
in the Global Medical Distribution industry.

( Industry Median: 26.70 vs. MCK: 5.12 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MCK' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 3.59  Med: 12.43 Max: 38.54
Current: 5.12
3.59
38.54
PB Ratio 2.66
MCK's PB Ratio is ranked lower than
61% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 2.33 vs. MCK: 2.66 )
Ranked among companies with meaningful PB Ratio only.
MCK' s PB Ratio Range Over the Past 10 Years
Min: 1.31  Med: 2.91 Max: 6.98
Current: 2.66
1.31
6.98
PS Ratio 0.15
MCK's PS Ratio is ranked higher than
88% of the 59 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.03 vs. MCK: 0.15 )
Ranked among companies with meaningful PS Ratio only.
MCK' s PS Ratio Range Over the Past 10 Years
Min: 0.08  Med: 0.18 Max: 0.32
Current: 0.15
0.08
0.32
Price-to-Free-Cash-Flow 11.79
MCK's Price-to-Free-Cash-Flow is ranked higher than
76% of the 25 Companies
in the Global Medical Distribution industry.

( Industry Median: 19.74 vs. MCK: 11.79 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MCK' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 5.4  Med: 12.26 Max: 41.89
Current: 11.79
5.4
41.89
Price-to-Operating-Cash-Flow 9.64
MCK's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 32 Companies
in the Global Medical Distribution industry.

( Industry Median: 17.77 vs. MCK: 9.64 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MCK' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.87  Med: 10.23 Max: 89.13
Current: 9.64
4.87
89.13
EV-to-EBIT 5.58
MCK's EV-to-EBIT is ranked higher than
96% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 15.56 vs. MCK: 5.58 )
Ranked among companies with meaningful EV-to-EBIT only.
MCK' s EV-to-EBIT Range Over the Past 10 Years
Min: 4.9  Med: 11.3 Max: 22.1
Current: 5.58
4.9
22.1
EV-to-EBITDA 4.88
MCK's EV-to-EBITDA is ranked higher than
96% of the 48 Companies
in the Global Medical Distribution industry.

( Industry Median: 11.09 vs. MCK: 4.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
MCK' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.3  Med: 9.1 Max: 16.3
Current: 4.88
4.3
16.3
EV-to-Revenue 0.18
MCK's EV-to-Revenue is ranked higher than
87% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.09 vs. MCK: 0.18 )
Ranked among companies with meaningful EV-to-Revenue only.
MCK' s EV-to-Revenue Range Over the Past 10 Years
Min: 0.1  Med: 0.2 Max: 0.4
Current: 0.18
0.1
0.4
PEG Ratio 0.27
MCK's PEG Ratio is ranked higher than
97% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.92 vs. MCK: 0.27 )
Ranked among companies with meaningful PEG Ratio only.
MCK' s PEG Ratio Range Over the Past 10 Years
Min: 0.15  Med: 1.15 Max: 9.75
Current: 0.27
0.15
9.75
Shiller PE Ratio 18.94
MCK's Shiller PE Ratio is ranked higher than
60% of the 20 Companies
in the Global Medical Distribution industry.

( Industry Median: 27.77 vs. MCK: 18.94 )
Ranked among companies with meaningful Shiller PE Ratio only.
MCK' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.91  Med: 29.3 Max: 51.86
Current: 18.94
14.91
51.86
Current Ratio 1.05
MCK's Current Ratio is ranked lower than
88% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.48 vs. MCK: 1.05 )
Ranked among companies with meaningful Current Ratio only.
MCK' s Current Ratio Range Over the Past 10 Years
Min: 1.03  Med: 1.27 Max: 1.71
Current: 1.05
1.03
1.71
Quick Ratio 0.61
MCK's Quick Ratio is ranked lower than
82% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.04 vs. MCK: 0.61 )
Ranked among companies with meaningful Quick Ratio only.
MCK' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 0.66 Max: 0.94
Current: 0.61
0.52
0.94
Days Inventory 30.22
MCK's Days Inventory is ranked higher than
68% of the 56 Companies
in the Global Medical Distribution industry.

( Industry Median: 39.35 vs. MCK: 30.22 )
Ranked among companies with meaningful Days Inventory only.
MCK' s Days Inventory Range Over the Past 10 Years
Min: 29.7  Med: 31.71 Max: 32.98
Current: 30.22
29.7
32.98
Days Sales Outstanding 35.47
MCK's Days Sales Outstanding is ranked higher than
82% of the 50 Companies
in the Global Medical Distribution industry.

( Industry Median: 64.74 vs. MCK: 35.47 )
Ranked among companies with meaningful Days Sales Outstanding only.
MCK' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.36  Med: 26.51 Max: 32.33
Current: 35.47
22.36
32.33
Days Payable 64.19
MCK's Days Payable is ranked lower than
57% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 68.40 vs. MCK: 64.19 )
Ranked among companies with meaningful Days Payable only.
MCK' s Days Payable Range Over the Past 10 Years
Min: 45.42  Med: 54.8 Max: 60.47
Current: 64.19
45.42
60.47

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.83
MCK's Dividend Yield % is ranked lower than
70% of the 67 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.73 vs. MCK: 0.83 )
Ranked among companies with meaningful Dividend Yield % only.
MCK' s Dividend Yield % Range Over the Past 10 Years
Min: 0.35  Med: 0.7 Max: 1.42
Current: 0.83
0.35
1.42
Dividend Payout Ratio 0.06
MCK's Dividend Payout Ratio is ranked higher than
95% of the 42 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.45 vs. MCK: 0.06 )
Ranked among companies with meaningful Dividend Payout Ratio only.
MCK' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.05  Med: 0.13 Max: 0.17
Current: 0.06
0.05
0.17
3-Year Dividend Growth Rate 6.80
MCK's 3-Year Dividend Growth Rate is ranked lower than
66% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 12.70 vs. MCK: 6.80 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
MCK' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -21.7  Med: 0 Max: 44.2
Current: 6.8
-21.7
44.2
Forward Dividend Yield % 0.96
MCK's Forward Dividend Yield % is ranked lower than
69% of the 61 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.67 vs. MCK: 0.96 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 1.21
MCK's 5-Year Yield-on-Cost % is ranked lower than
84% of the 68 Companies
in the Global Medical Distribution industry.

( Industry Median: 3.81 vs. MCK: 1.21 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
MCK' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.51  Med: 1.02 Max: 2.07
Current: 1.21
0.51
2.07
3-Year Average Share Buyback Ratio 3.00
MCK's 3-Year Average Share Buyback Ratio is ranked higher than
95% of the 39 Companies
in the Global Medical Distribution industry.

( Industry Median: -0.90 vs. MCK: 3.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MCK' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -47  Med: -0.15 Max: 5.7
Current: 3
-47
5.7

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 0.58
MCK's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
93% of the 29 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.61 vs. MCK: 0.58 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MCK' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.55  Med: 1 Max: 30.68
Current: 0.58
0.55
30.68
Price-to-Intrinsic-Value-DCF (Earnings Based) 0.28
MCK's Price-to-Intrinsic-Value-DCF (Earnings Based) is ranked higher than
92% of the 12 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.33 vs. MCK: 0.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-DCF (Earnings Based) only.
MCK' s Price-to-Intrinsic-Value-DCF (Earnings Based) Range Over the Past 10 Years
Min: 0.26  Med: 1.47 Max: 2.92
Current: 0.28
0.26
2.92
Price-to-Median-PS-Value 0.84
MCK's Price-to-Median-PS-Value is ranked higher than
55% of the 47 Companies
in the Global Medical Distribution industry.

( Industry Median: 0.95 vs. MCK: 0.84 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MCK' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.51  Med: 1.01 Max: 1.92
Current: 0.84
0.51
1.92
Price-to-Peter-Lynch-Fair-Value 0.31
MCK's Price-to-Peter-Lynch-Fair-Value is ranked higher than
94% of the 17 Companies
in the Global Medical Distribution industry.

( Industry Median: 1.48 vs. MCK: 0.31 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MCK' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.33  Med: 1.18 Max: 72.67
Current: 0.31
0.33
72.67
Earnings Yield (Greenblatt) % 17.92
MCK's Earnings Yield (Greenblatt) % is ranked higher than
97% of the 60 Companies
in the Global Medical Distribution industry.

( Industry Median: 5.56 vs. MCK: 17.92 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MCK' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.5  Med: 8.9 Max: 20.6
Current: 17.92
4.5
20.6
Forward Rate of Return (Yacktman) % 32.19
MCK's Forward Rate of Return (Yacktman) % is ranked higher than
91% of the 35 Companies
in the Global Medical Distribution industry.

( Industry Median: 10.23 vs. MCK: 32.19 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MCK' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -0.6  Med: 21.4 Max: 95.5
Current: 32.19
-0.6
95.5

More Statistics

Revenue (TTM) (Mil) $201,955.00
EPS (TTM) $ 20.48
Beta1.25
Short Percentage of Float3.13%
52-Week Range $133.82 - 169.29
Shares Outstanding (Mil)208.47

Analyst Estimate

Mar18 Mar19 Mar20
Revenue (Mil $) 205,706 212,183 223,475
EPS ($) 12.07 12.91 14.11
EPS without NRI ($) 12.07 12.91 14.11
EPS Growth Rate
(Future 3Y To 5Y Estimate)
-5.47%
Dividends per Share ($) 1.25 1.33 1.72

Piotroski F-Score Details

Piotroski F-Score: 44
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyN
Higher Current Ratio yoyN
Less Shares Outstanding yoyY
Higher Gross Margin yoyN
Higher Asset Turnover yoyN

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}